Studies have reported that upregulation of ECI2 expression can promote the progression of prostate cancer, and its high expression is considered a potential therapeutic target for prostate cancer.[46] However, the specific role and mechanism of action of ECI2 in IDD remain unclear and require further investigation. The gene discussed is ECI2; the disease is prostate carcinoma.